Hydrogen’s Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen-FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrest.
Victoria Habet, Tysen DeWaard, Krislyn M Boggs, Alix Fetch, Bao Nguyen Puente, Lynn A Sleeper, John N Kheir · Trials · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This publication examined hydrogen gas using the study design reported by the authoritative source. No study results are reported because this publication is a protocol.
What the Study Plans to Test
The Hydrogen-FAST trial investigates the feasibility and safety of inhaled hydrogen gas as an adjunctive therapy during ECPR in patients with congenital heart disease (CHD).
Planned Hydrogen Intervention
Sites must have an ECMO care team (e.g., respiratory therapists, nurses) who can assist with randomization procedures and administration of hydrogen gas.
Planned Outcomes
Feasibility, measured as the percentage of the first 72 h post-arrest in which hydrogen is successfully administered, with feasibility defined as a mean percentage of ≥90%, and safety, evaluated through incidence rates of treatment-related serious adverse events (SAEs). clinical outcomes including survival to discharge, ICU length of stay, functional status at 6 months, neurologic function, and markers of ischemic injury.
Current Study Status
This publication describes a planned or ongoing study; H2HUBB presents it as a protocol rather than as completed outcome evidence.